These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 19818166)

  • 1. Anti-tumour necrosis factor therapy and B cells in rheumatoid arthritis.
    Leandro MJ
    Arthritis Res Ther; 2009; 11(5):128. PubMed ID: 19818166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B Lymphocytes in Rheumatoid Arthritis and the Effects of Anti-TNF-α Agents on B Lymphocytes: A Review of the Literature.
    Pala O; Diaz A; Blomberg BB; Frasca D
    Clin Ther; 2018 Jun; 40(6):1034-1045. PubMed ID: 29801753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response.
    Adlowitz DG; Barnard J; Biear JN; Cistrone C; Owen T; Wang W; Palanichamy A; Ezealah E; Campbell D; Wei C; Looney RJ; Sanz I; Anolik JH
    PLoS One; 2015; 10(6):e0128269. PubMed ID: 26047509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No B cells--no active RA? Advances in B cell depletion in RA--repeated therapy under conditions of clinical practice.
    Dörner T; Burmester GR
    Rheumatology (Oxford); 2007 Apr; 46(4):563-4. PubMed ID: 17337751
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunological therapies for rheumatoid arthritis.
    Edwards CJ
    Br Med Bull; 2005; 73-74():71-82. PubMed ID: 16174791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B cell therapies for rheumatoid arthritis: beyond B cell depletion.
    Calero I; Nieto JA; Sanz I
    Rheum Dis Clin North Am; 2010 May; 36(2):325-43. PubMed ID: 20510237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B lymphocyte depletion therapy with rituximab in rheumatoid arthritis.
    Edwards JC; Leandro MJ; Cambridge G
    Rheum Dis Clin North Am; 2004 May; 30(2):393-403, viii. PubMed ID: 15172048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-TNF-alpha monoclonal antibodies in the treatment of rheumatoid arthritis].
    Mugnier B; Bouvenot G
    Rev Med Interne; 2000 Oct; 21(10):854-62. PubMed ID: 11075394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Double-blind trial of the effectiveness of antibodies to interferon-gamma and tumor necrosis factor-alpha in rheumatoid arthritis (preliminary results)].
    Lukina GV; Sigidin IaA; Skurkovich SV; Skurkovich BS
    Ter Arkh; 2001; 73(5):12-5. PubMed ID: 11517739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis.
    Keystone EC
    Rheum Dis Clin North Am; 2001 May; 27(2):427-43. PubMed ID: 11396102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated B-cell depletion in clinical practice.
    Edwards JC; Cambridge G; Leandro MJ
    Rheumatology (Oxford); 2007 Sep; 46(9):1509. PubMed ID: 17623746
    [No Abstract]   [Full Text] [Related]  

  • 13. Peripheral blood lymphocytes from patients with rheumatoid arthritis are differentially sensitive to apoptosis induced by anti-tumour necrosis factor-alpha therapy.
    Coury F; Ferraro-Peyret C; Le Cam S; Guerin S; Tebib J; Sibilia J; Bienvenu J; Fabien N
    Clin Exp Rheumatol; 2008; 26(2):234-9. PubMed ID: 18565243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
    Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL
    Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
    Manadan AM; Block JA
    Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
    Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
    Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNF-blocking therapies: an alternative mode of action?
    Choo-Kang BS; Hutchison S; Nickdel MB; Bundick RV; Leishman AJ; Brewer JM; McInnes IB; Garside P
    Trends Immunol; 2005 Oct; 26(10):518-22. PubMed ID: 16087401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biopharmaceuticals in the treatment of rheumatoid arthritis].
    Baslund B; Bendtzen K
    Ugeskr Laeger; 2008 Jun; 170(24):2108-10. PubMed ID: 18572481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific therapy to regulate inflammation in rheumatoid arthritis: molecular aspects.
    García-Hernández MH; González-Amaro R; Portales-Pérez DP
    Immunotherapy; 2014; 6(5):623-36. PubMed ID: 24896630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents.
    Halvorsen EH; Haavardsholm EA; Pollmann S; Boonen A; van der Heijde D; Kvien TK; Molberg Ø
    Ann Rheum Dis; 2009 Feb; 68(2):249-52. PubMed ID: 18723564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.